Amarantus Provides Update on Elto Pharma Capital Formation Plan NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire –  Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding...

Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....

Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings,...